Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
This article reviews existing data on the IHC biomarker aspects of studies using these drugs in non–small-cell lung cancer (NSCLC) and considers the challenges ahead, should these drug/IHC assay combinations reach routine practice. For each the known biomarker assays in development, there is a different monoclonal IHC antibody clone, produced by one of two diagnostics companies. Each test requires proprietary staining platforms and uses different definitions of a “positive” test for PD-L1 expression, on tumor cells and, in one test, also on tumor infiltrating immune cells. There are still considerable gaps in our kno...
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: State of the Art: Concise Review Source Type: research
Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy
As the leading cause of cancer death worldwide, lung cancer continues to impose a major burden on healthcare systems and cause significant challenges for clinicians and patients. Most patients present with advanced disease at the time of diagnosis and have a poor prognosis, with the vast majority surviving less than 5 years. Although new therapies have been introduced in recent years that target molecular disease drivers present in a subset of patients, there is a significant need for treatments able to improve response and extend survival while minimizing effects on quality of life. Recent evidence of clinical efficacy fo...
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: State of the Art: Concise Review Source Type: research
In This Issue/Research Watch/News in Brief/News From the Iaslc Tobacco Control Committee
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: In This Issue/Research Watch/News in Brief/News From the Iaslc Tobacco Control Committee Source Type: research
Reply to “Better Prognostic Models May Result in Improved Patient Selection for Adjuvant Therapies After Complete Resection of Solitary Fibrous Tumors of the Pleura”
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
Reply to “MiR-205 and miR-375 microRNA Assays to Distinguish Squamous Cell Carcinoma From Adenocarcinoma in Lung Cancer Biopsies”
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
MicroRNA Assays for Diagnosis Lung Cancer Biopsy
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
Reply to “18F-Choline PET-CT in the Management of Lung Cancer and Mucinous Tumors?”
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
Beware of the “Bronchocele,” Particularly in Patients with a History or Risk Factors for a Mucinous Carcinoma: A Response to the Article “Resection of a Solitary Pulmonary Metastasis from Prostatic Adenocarcinoma Misdiagnosed as a Bronchocele: Usefulness of 18F-Choline and 18F-FDG PET/CT” by Calais et al.
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
Metabolomics a Novel Biomarker in Lung Cancer
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non–Small-Cell Lung Cancer
Patients: With advanced non–small-cell lung cancer (NSCLC) harboring, the anaplastic lymphoma kinase (ALK) gene rearrangement often responds impressively to ALK inhibitors, such as crizotinib. Acquired tumor resistance to ALK inhibition develops after a median progression-free survival of 7.7 to 10.9 months, with several mechanisms of resistance already described. Second generation ALK inhibitors, such as ceritinib, may overcome some of these mechanisms and have known efficacy in brain metastases. Their effect on intramedullary spinal cord metastases, a rare form of central nervous system metastases, is unknown. (Source:...
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Case Reports Source Type: research
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Case Reports Source Type: research
BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Case Reports Source Type: research
Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib
No abstract available (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Image of the Month Source Type: research
Stereotactic Body Radiotherapy Using a Radiobiology-Based Regimen for Stage I Non–Small-Cell Lung Cancer: Five-Year Mature Results
Conclusions: Our first prospective SBRT study yielded reasonable local control and overall survival rates and acceptable toxicity. Refinement of the protocol including dose escalation may lead to better outcome. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - May 23, 2015 Category: Cancer & Oncology Tags: Brief Report Source Type: research
